Carl Hull, Thomas MacMahon
Former Gen-Probe Chairman and CEO Carl Hull and former Laboratory Corporation of American Chairman and CEO Thomas MacMahon have joined the board of Ortho Clinical Laboratories as independent members.
Hull has more than 30 years of experience in the life sciences and diagnostics markets, and in addition to his stint at Gen-Probe, he held executive positions at Applied Biosystems, Applied Imaging, Ventana Medical Systems, and Abbott Diagnostics.
MacMahon is currently an executive partner at Foundation Medical Partners. He began his career at Roche.
Also joining Ortho Clinical Diagnostics' board as independent members are former Fenwal President and CEO Ron Labrum and Covidien President and CEO José Almeida.
Robert Nussbaum has been appointed chief medical officer of Invitae, effective Aug. 1. A board-certified internist and medical geneticist, Nussbaum was most recently chief of the Division of Genomic Medicine at the University of California, San Francisco Institute for Human Genetics. Prior to this, he was chief of the Genetic Disease Research Branch of the National Human Genome Research Institute.
Lars Sørensen is resigning from Thermo Fisher Scientific's board, effective July 1, citing increasing commitments associated with his role as president and CEO of Novo Nordisk. Sørensen joined Thermo Fisher's board in July 2011.
Transplant Genomics has appointed Roy First its chief medical officer in preparation of the company's launch of its first product, the TruGraf Blood Test. First was most recently vice president and therapeutic area leader for transplantation at Astellas Pharma Global Development. He is a past president of the American Society of Transplantation.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.